For adolescent males with severe obesity, bariatric surgery is associated with an increase in testosterone concentrations.
Researchers explored the association between circulating sex hormones, motor unit characteristics, and exercise in older men, including master athletes.
Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.
Study finds increased risk for severe disease and mortality among men hospitalized with COVID-19 and low testosterone and high estradiol-to-testosterone ratio.
Study authors hypothesized that longer-acting testosterone replacement therapy will have significant impact on suppressing HPG axis compared with short-acting TRT preparations.
Overweight or obese men frequently have low serum testosterone concentrations, which is associated with increased risk of type 2 diabetes.
In a study, most symptomatic hypogonadal men treated with Natesto, a short-acting 4.5% nasal testosterone gel, attained normal testosterone levels at 6 months while preserving sperm counts.
Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.
The American College of Physicians has issued a set of recommendations to clarify the potential benefits and harms of testosterone therapy in men with age-related low testosterone.
Older men receiving testosterone treatment with higher waist-to-hip ratio experience greater increases in noncalcified coronary plaque volume.
For men with and without hypogonadism, testosterone therapy is associated with an increased short-term risk for venous thromboembolism.